filmov
tv
The Evolution of ALK/ROS1-Targeted Therapy in NSCLC
Показать описание
Corey Langer, MD, discusses the nature of EML4-ALK and ROS1 gene rearrangements, typical patient presentation, and the evolution of ALK inhibitors in non–small cell lung cancer.
0:04:05
0:03:31
0:05:30
0:40:53
0:06:41
0:30:32
0:04:49
0:03:31
0:22:51
0:03:55
0:01:36
0:31:43
0:06:27
1:07:25
0:04:37
0:22:46
0:01:45
0:18:23
0:00:56
0:01:27
0:03:52
0:02:39
0:00:39
0:33:52